Table 1.
Characteristics of the BASE-II participants included in the present study
| Men (n = 181) | Women (n = 256) | |
|---|---|---|
| Age [years] | 70 (67–73) | 68 (66–70) |
| BMI [NR 18–25 kg/m2] | 26.9 (25.0–29.0) | 25.8 (23.4–28.6) |
| Body weight [kg] | 82.1 (76.4–90.5) | 68.0 (62.0–76.3) |
| Height [cm] | 175.7 (171.0–180.0) | 163.2 (158.9–168) |
| HbA1c [NR < 5.7%] | 5.5 (5.2–5.7) | 5.4 (5.2–5.7) |
| HOMA-IR (NR < 1.9) | 2.0 (1.4–3.0) | 1.7 (1.2–2.5) |
| ISIOGTT (NR > 4)a | 5.6 (3.3–8.7) | 5.7 (3.8–8.3) |
| Fasting PG (mg/dL) | 102.5 (88.0–125.0) | 104.0 (89.0–124.0) |
| PG in 75-g OGTT at 120 min (mg/dL) | 94.0 (87.0–102.0) | 89.0 (84.0–96.0) |
| Fasting Insulin in 75-g OGTT (mg/dL) | 9.0 (6.3–12.3) | 7.6 (5.7–10.4) |
| Insulin in 75-g OGTT at 120 min (mg/dL) | 42.9 (25.6–72.4) | 44.9 (29.7–67.3) |
| Triglycerides (NR </= 200 mg/dL) | 104 (77–143) | 91 (73–119) |
| HDL cholesterol (NR male/female =/> 35/45 mg/dL) | 53 (45–65) | 70 (57–79) |
| LDL cholesterol (NR < 130 mg/dL) | 122 (100–147) | 136 (112–162) |
| Cholesterol (NR < 200 mg/dL) | 201 (177–228) | 232 (202–256) |
| Obesity [n, %] | 28 (15.5) | 49 (19.1) |
| T2D [n, %] | 20 (11.0) | 17 (6.6) |
| HOMA-IR > 1.9 [n, %] | 21 (12.1) | 22 (9.1) |
| ISIOGTT < 4 [n, %]a | 51 (31.8) | 65 (28.6) |
| CRP (NR < 5 mg/L) | 1.2 (0.7–2.3) | 1.2 (0.6–2.0) |
| Basophils (NR 0–0.2 G/L) | 0.05 (0.05–0.05) | 0.05 (0.05–0.05) |
| Eosinophils (NR 0.02–0.5 G/L) | 0.18 (0.11–0.24) | 0.15 (0.10–0.220) |
| Leukocytes (NR 3.9–10.5 G/L) | 5.7 (4.7–6.7) | 5.5 (4.6–6.4) |
| Monocytes (NR 0.1–0.9 G/L) | 0.45 (0.36–0.53) | 0.35 (0.29–0.43) |
| Neutrophils (NR 1.5–7.7 G/L) | 3.2 (2.7–4.0) | 3.1 (2.5–3.7) |
Categorical data are presented as percentages. None of the continuous variables were normally distributed; thus, values are presented as median and interquartile range. BMI body mass index, HOMA-IR homeostasis model assessment of insulin resistance. ISIOGTT insulin sensitivity index, NR normal range, OGTT oral glucose tolerance test, PG plasma glucose, T2D type 2 diabetes. aISIOGTT was not assessed for participants with type 2 diabetes